The clinical, biochemical, radiographic, histologic and prognostic features of aluminum-related bone disease, the sources and methods of removal of aluminum, the differences between epidemic and sporadic forms, and whether or not the condition should be referred to as aluminum-induced bone disease have all received a great deal of recent attention (1-8). Early reports identified three sites for aluminum deposition in bone -the junction between osteoid and mineralized bone, cement lines, and the neutral or quiescent bone surface (9-13). In the most comprehensive recent account the deposition of aluminum in bone is vaguely described as either on the bone surface or diffusely within the bone (7), but even in this era of molecular biology old fashioned anatomic precision should not be disdained. The purpose of this editorial review is to re-emphasize the importance of knowing exactly where aluminum is to be found in bone and the inferences that can be drawn from such knowledge.
The normal bone remodeling cycle
The different sites of aluminum localization can best be understood in relation to the normal cycle of adult bone remodeling (14, 15) . Most bone surfaces are quiescent with respect to remodeling, covered by flat lining cells that separate the bone mineral from the bone marrow. Beneath the cells lies the endosteal membrane, a thin layer of loosely textured collagencontaining unmineralized connective tissue, sometimes misleadingly referred to as osteoid, a term that should The International Journal Of Artificial Organs / Vol. 11 / no. 2, 1988/ pp. [79] [80] [81] [82] [83] [84] [85] [86] [87] [88] [89] [90] be restricted to bone matrix whose normal fate is to become fully mineralized. The most superficial layer of mineralized bone matrix is the lamina limitans, which is denser than the more deeply lying bone matrix, although this difference can be demonstrated only after demineralization. The conversion of a region of bone surface from quiescence to remodeling activity is termed activation, and the frequency with which this event occurs is the main determinant of the whole body rate of bone turnover. Following proliferation, osteoclast precursor cells migrate to the region in question, where the lining cells first secrete collagenase to digest the endosteal membrane (16) and then change shape to cover a smaller area. Precursor cells are attracted chemotactically to the exposed mineralized bone surface, where they fuse into multinucleated osteoclasts.
The team of osteoclasts that has been assembled initiated focal bone resorption to form a cavity on the bone surface. When the cavity has reached a depth of approximately 20 Jim, the osteoclasts are gradually replaced by mononuclear cells, but whether these are disaggregated osteoclasts or unfused precursor cells is unknown (15) . Resorption continues with diminishing speed and eventually stops when the cavity has reached a mean depth of approximately 50 Jim. The floor of the cavity is smoothed off and becomes covered by a thin layer of cement substance, which is a specialized form of bone matrix that is relatively collagen poor but eventually becomes more highly mineralized than the matrix generally (10, 14) . During the reversal period between completion of resorption and the start of formation the cavity contains a variety of mononuclear cells, but their origin, relationship to mononuclear resorbing cells, function and fate are unknown. There also appear cells with poorly staining cytoplasm and large nuclei that are probably preosteoblasts (15) . When these preparations are completed, a team of osteoblasts are assembled on the floor of the cavity and begin to deposit osteoid ( Fig. 1 ). About 10-15 days later, when the thickness of the osteoid layer has reached 15-20 Jim, mineralization begins and matrix synthesis begins to slow down. The osteoid seam gets progressively thinner and eventually disappears as all the osteoid formed becomes mineralized.
The cement substance on the floor of a cavity is a two-dimensional surface in three-dimensional space, but in a two-dimensional histologic section it is represented by a one-dimensional profile -the cement line that demarcates moieties of bone made at different times. The cement line can be located approximately by the change in lamellar orientation under polarized light, but positive histochemical identification is more accurate (17) . Cement lines in mature bone were at one time the borders of resorption cavities and indicate the furthest extent to which a previous team of osteoclasts eroded from the surface. Similarly, the distance of the cement line from the present bone surface, referred to as wall thickness, indicates the depth of bone laid down at that location by a previous team of osteoblasts. Once the cement line has been deposited and buried by new bone it remains fixed in location and persists until it is resorbed during a subsequent cycle of remodeling.
The junction between osteoid and mineralized bone has been termed the zone of demarcation (14) , because the transition occurs gradually over a band of several micrometers thickness rather than abruptly. It is now more commonly referred to as the osteoidmineralized bone interface (18) or simply the bone interface (19) . The interface is also frequently termed the mineralization front, but this obscures the important distinction between an anatomic location and a physiologic activity that mayor may not be occurring at that location. The mineralization front refers to the thin, coarsely granular layer of most recently deposited young mineral not yet fully incorporated into the crystal structure of bone. It can be identified by various histochemical procedures but most clearly by the uptake of tetracycline, detectable by its fluorescence (20) . Although the mineralization front is located invariably at the bone interface, the latter continues to exist even if mineralization ceases prematurely and the front disappears. Between the onset of matrix synthesis and the onset of mineralization the bone interface and the cement line are identical in location, but the bone interface moves progressively away from the cement line once mineralization begins and becomes the new bone surface when mineralization is completed (Fig. 1 ).
The location and timing of aluminum deposition in bone
Several methods have been used to study aluminum storage in bone. A rise in plasma aluminum after de-80 feroxamine infusion reflects the total body stores of aluminum regardless of location; if the rise is small, severe aluminum-related bone disease is unlikely (6, 21, 22) , but similar information is provided by the baseline pre-infusion levels (23) . Chemical analysis of total bone aluminum was an important step in the discovery and description of aluminum-related bone disease (1-7), but by itself can no longer justify an invasive procedure (24, 25) . Aluminum can be identified in specific sites in bone by either histochemical (11) (12) (13) 25) or physical (9, 10, 26) methods. The former are comparatively simple and widely available, but have relatively low sensitivity and specificity. They can be negative when aluminum is detectable by chemical analysis (25, 27) , and can react with other metals (28) . Physical methods require complex and expensive equipment, but are much more sensitive and discriminate unequivocally between different elements (29) . Consequently, they provide a more reliable basis for generalization concerning aluminum localization, even though fewer data are available.
Three physical methods have been applied -electron probe x-ray microanalysis (9, 10, 13, 18, 28, 30, 31) , secondary ion mass spectrometry or analytical ion microscopy (10, 26, 30) and laser microprobe mass analysis (26, 32) . These methods are based on different physical principles and differ in sensitivity, resolution, and suitability for measuring focal concentration (29) , but have given essentially identical results. With all three methods aluminum is located almost exclusively at the bone interface in patients with osteomalacia, and at cement lines in patients with osteitis fibrosa. Aluminum is also sometimes found at other sites, such as deeply within both mineralized bone and osteoid, but at very low levels, although amounts of aluminum in osteoblast mitochondria that are quantitatively trivial could have great functional significance (30) . In particular, using physical methods, there have been no reports of preferential accumulation of aluminum on the quiescent bone surface, a site where we and others (12, 33) have observed positive histochemical reactions for aluminum.
Before explaining the possible discrepancy between physical and histochemical methods concerning bone surface aluminum, the significance of the locations for which the two methods are in agreement will be examined. The bone interface and the cement line are commonly regarded as different sites, but reference 
) has increased and osteoid thickness has got smaller. A mineralization front would be demonstrable along most of the bone interface. At time 4 the bone interface has reached the location of the original bone surface and all the old bone has been replaced by new bone; mineralized bone thickness is now identical with wall thickness (W.Th.]. Note that the cement line remains unchanged in location throughout this sequence of events.
to the bone remodeling cycle strongly suggests that they both represent deposition of aluminum at the same place, at the same time, and by the same mechanism, differing only in the events that follow (Fig. 2 ). If aluminum deposition always occurs on the cement line during the late reversal period, it will be present at the bone interface when matrix synthesis begins. If the matrix becomes mineralized before the bone is examined, the aluminum will be observed at the cement line, separated from the bone surface by a layer of mineralized bone. On the other hand, if mineralization fails to occur before the bone is examined, the aluminum will be observed at the bone interface, separated from the bone surface by a layer of osteoid ( Fig. 2 ). In this circumstance there will be no mineralization front, so that this term should not be used to identify the location of aluminum, although this is a very common mistake.
Different mechanisms for aluminum fixation at the bone interface and at the cement line were proposed because tetracycline is commonly observed at the former location, but not at the latter (10) . But this difference is easily explained. The opportunity for aluminum fixation in bone continues for months or years, but the opportunity for tetracycline fixation is confined to the usually brief periods of therapeutic or diagnostic administration. The site of tetracycline deposition at the bone interface will be indistinguishable from the site of the cement line on Iy for the fi rst 1-2 days after the start of mineralization, since the minerai apposition rate at this time is 1.5-2.0 pm/day, much higher than the average rate throughout the osteoid seam life span (14, 15) . Because this life span is normally about 100 days, the particular circumstance described will apply to less than 2% of the osteoid seams present when tetracycline was given. Consequently, a band of tetracycline fluorescence buried by new bone will only rarely be observed at or close to the cement line. The absence of stainable aluminum from mineralized bone between the cement line and the bone surface, where tetracycline labels are often found, implies that aluminum binds preferentially to some constituent of the cement substance and that once mineralization begins, aluminum already deposited on the cement line is trapped, but conditions favorable to further accumulation of aluminum are no longer present. If matrix synthesis occurs, but mineralization is prevented by concurrent vitamin D deficiency, aluminum deposition on the cement line/bone interface is enhanced (34, 35) ; presumably aluminum can diffuse easily through even a thickened layer of unmineralized bone matrix. The extent of aluminum deposition evidently depends on the length of time for which the cement line/bone interface remains accessible to the circulation. This time will be increased either by a delay in the onset of bone formation and consequent prolongation of the reversal period (14, 15) , or by a delay in the onset of mineralization, even if matrix synthesis has begun, but in either case the site and mechanism of aluminum fixation are the same.
Returning to the question of aluminum deposition on the quiescent bone surface, two factors seem relevant, both dependent on chemical similarities between aluminum and iron. Positive histochemical reactions for iron in bone are common in dialysis patients, but they occur mainly on the bone surface, whether mineralized (quiescent surface), or unmineralized (osteoid surface) (6, 18, 36) . Iron is occasionally seen at the bone interface (18, 32, 36) , but rarely (in our experience, never) in the absence of aluminum. As expected, iron is also frequently observed in bone marrow cells. Deposition of iron is similar in all states of iron overload and is not specific to renal failure; variations in the extent of iron deposition presumably reflect policy differences between dialysis centers concerning the control of iron stores (28, 37) . Aluminum and ferric iron are both trivalent and when either or both are present in excess they tend to accumulate non-specifically in the same locations (32, (36) (37) (38) (39) . Furthermore, most histochemical methods for aluminum give aberrant results when excess iron is also present (32, 40) and it can be difficult to distinguish between aluminum alone, aluminum and iron together, and iron alone.
The preceding discussion implies that there are fundamental differences between aluminum at the cement line/bone interface and aluminum on the quiescent surface, but this might not be so if aluminum could change its location with time. Consideration of this possibility requires more detailed examination of exactly what it is that moves when we speak of the bone interface moving away from the cement line (41) . Most of the movement is of organization rather than structure, since once the major components of matrix and mineral are deposited they stay in the same place. This is why cement lines and tetracycline labels can remain intact for decades if the rate of bone turnover is low. But there is also movement of structure, since all the osteoblasts in a team assemble at the start and move with the advancing edge of the bone matrix, leaving some behind as osteocytes (14) . Many substances that participate in the process of mineralization are present in much higher concentration at the mineralization front than in mature bone (42, 43) .
Organic molecules, such as phospholipids, could be continually destroyed and replaced, but elements such as zinc must presumably move with the mineralization front through tissue space (41); could aluminum deposited on the cement line end up on the bone surface in a similar manner?
Zinc at the bone interface is probably in the form of a metallo-enzyme and local re-utilization of zinc for continued enzyme synthesis by osteoblasts appears plausible. Aluminum at the bone interface is probably in the form of hexagonal structures 20-100 nm in diameter that are distinct from hydroxyapatite crystals and contain phosphate but not calcium (30, 44) . Although these structures were described as within mineralization nuclei (9) and in the "mineralizing layer" of osteoid (30, 44) , the mineralization front detectable by light microscopy (20) was markedly reduced in extent or absent, and the ultrastructural characteristics of the bone interface and adjacent osteoid resembled those previously described in osteomalacia (45) . It seems much more likely that the aluminumcontaining particles would remain in situ rather than migrate outwards if mineralization should resume. Consequently, all available data are consistent with the conclusion that aluminum is deposited in bone by two fundamentally different mechanisms -specific binding induced by some constituent of cement substance, and non-specific accumulation, usually but not invariably in association with iron, on the quiescent bone surface.
The pathogenesis of aluminum-related bone disease
Current schemes for classifying renal bone disease are based largely on observations restricted to patients with renal failure (6, (46) (47) (48) , but my own approach is derived from experience with all varieties of metabolic bone disease (49) . This experience has indicated the central importance of osteoid thickness and adjusted apposition rate (previously termed corrected or effective apposition rate) in the definition of impaired mineralization (50, 51) . Adjusted apposition rate (19) is the mineral apposition rate corrected for the proportion of osteoid that is currently mineralizing and so averaged over the osteoid seam life span. In a steady state and in the absence of osteomalacia, it is the best estimate available from a bone biopsy of the mean rate of matrix apposition by teams of osteoblasts (43) . In normal subjects and in patients with osteoporosis or hyperparathyroidism (primary or secondary), osteoid thickness varies directly with adjusted apposition rate (50), but the essential kinetic feature of impaired mineralization is that the slope of the relationship is reversed, osteoid thickness increasing rather than decreasing as adjusted apposition rate falls (50, 51) .
Based on these observations, my criteria for generalized osteomalacia are the concurrence of mean values for osteoid thickness (corrected for section obliquity) of > 12.5 Jim, and mineralization lag time (osteoid thickness divided by adjusted apposition rate) of > 100 days, and osteoid volume> 10% of bone volume (51) . Others have independently reached very similar conclusions (52, 53) and these or similar criteria are now widely accepted (54, 55) . Increased osteoid thickness without prolongation of lag time can occur in hyperparathyroidism without impaired mineralization, and prolonged lag time with normal or reduced osteoid thickness and without osteoid accumulation are characteristic of the defect in osteoblast function in osteoporosis (50) . It is also useful to subdivide generalized osteomalacia according to the presence or absence of some double tetracycline labels, corresponding respectively to the premature cessation and complete failure of mineralization (51) . In the former case (stage i i ) there will be some mineralized bone between the thickened osteoid seam and the cement line, but in the latter case (stage iii), the bone interface will still be at the cement line.
This scheme also permits the recognition of two variant forms (51) . In focal osteomalacia, osteoid thickness increases earlier or to a relatively greater extent than osteoid surface; this is contrary to the usual sequence in vitamin D related osteomalacia, in which osteoid surface increases first because of secondary hyperparathyroidism (stage i; 51). In mild cases of focal osteomalacia, increased osteoid thickness and prolonged lag time are present only in a few locations. Osteomalacia due to exogenous toxins, including therapeutic agents such as sodium fluoride and etidronate, is frequently focal in character (51) . In atypical osteomalacia there is increased osteoid surface and volume and prolonged lag time in the absence of increased osteoid thickness, either focal or general. This reflects a more severe impairment of matrix apposition by osteoblasts than ordinarily occurs in vitamin D related osteomalacia and is probably a stage in the evolution of all forms of hypophosphatemic osteomalacia (51) .
These distinctions are especially pertinent to an understading of so-called aplastic bone disease (40, 46, 48) . Since the definition of this term makes no reference to osteoid thickness or mineralization lag time, it could include both focal and atypical osteo-malacia, as well as non-osteomalacic defects in osteoblast function typical of osteoporosis (50) . The latter two disorders are also included in the definition of so-called type 2 osteomalacia (47), in which osteoid maturation time, given by osteoid thickness divided by unadjusted apposition rate (19) , and referred to by these workers as direct mineralization lag time, is normal. Although generalized osteomalacia is the most characteristic form of bone disease found in patients with aluminum at the bone interface (18, 47, 49) , focal osteomalacia (56) (57) (58) , atypical osteomalacia (33, 47, 55) , hyperparathyroid bone disease without osteomalacia (57, 59, 60) , defective osteoblast function without osteomalacia or low turnover osteopenia (54, 55, 58) and combinations of these disorders (6, 46) can also be found.
Before examining the reasons for these differences, the evidence incriminating aluminum in etiology will be briefly summarized. The evidence is more clear-cut for the epidemic form due to dialysate contamination than for the sporadic form due to absorption of aluminum from antacids (3) . In many situations the concentration of aluminum in the dialysate, the bulk concentration and stainable extent of aluminum in bone, and the type of bone disease present are related. These relationships hold whether the composition of the dialysate reflects the geology of the natural water supply (1, 2, 61, 62) , intervention by municipal water authorities (2, 7, 63) , or improvements in water purification in particular dialysis centers (3, 62, 64, 65) . Furthermore, removal of aluminum, whether by chelation with deferoxamine (60) (61) (62) (63) (64) (65) (66) (67) (68) (69) or by renal transplantation (66, 70, 71) , is followed by improvement in the bone disease. Although none of these observations proves causation, it would be an extraordinary coincidence if in everyone of these diverse circumstances aluminum was simply a marker for some other substance, so far unidentified, that was the real culprit. The straightforward conclusion that aluminum itself is responsible is supported both by in vitro studies (72, 73) and by several designs of in vivo experiment in several different species (63, (74) (75) (76) (77) (78) (79) .
It is clear that exposure to aluminum is a necessary condition for aluminum-related bone disease, but that it is not a sufficient condition is equally clear from the morphologic evidence. The existence of aluminum-stained cement lines in patients with osteitis fibrosa, the increase in aluminum-stained cement lines after renal transplantation (70, 71) or deferoxamine therapy (68, 69) , indicating restoration of mineralization despite incomplete removal of aluminum, and the failure of aluminum at the bone interface to prevent resumption of mineralization after correction of vitamin D deficiency (35) all demonstrate that the simple presence of abundant aluminum at the cement line/bone interface does not by itself have any adverse effect on bone.
There may be a threshold concentration of aluminum (estimated at not less than 5 mg/g of dry bone) that must be exceeded for mineralization to be impaired (9) ; direct measurements of local aluminum concentrations in bone are sparse, but plasma aluminum levels are higher in the presence than in the absence of osteomalacia (6, 23) . Total bone aluminum is also higher in osteomalacia than in osteitis fibrosa (80) , but this likely reflects differences in the extent of aluminum staining; a consistent difference in the intensity of staining between the cement line and the bone interface has not yet been demonstrated either in patients or in animal models of aluminum administration. Furthermore, histologic changes can be so striking in relation to the small amounts of aluminum removed (67-69) that other factors can likely modify the effect of aluminum at the cement line/bone interface. Before considering what these factors might be, the abnormalities of bone cell function and the morphologic patterns of bone disease found in association with aluminum deposition must be examined in more detail.
A high concentration of aluminum at the cement line/bone interface is strategically placed to inhibit mineralization and so induce the most obvious defect in severe aluminum-related bone disease. Comparison of aluminum-related with vitamin D-related osteomalacia indicates that in the former, cessation of mineralization occurs earlier in the course of the disease (49) . As a result, retention of the second tetracycline label is less common and absence of any tetracycline fluorescence more common, osteoid surface is less increased and osteoid thickness relatively more increased, and the bone interface is more likely to remain at the cement line. But accumulation of aluminum during the late reversal period is also strategically timed to affect the nascent osteoblasts that are beginning to assemble; the presence of aluminum within osteoblasts was mentioned earlier (44) . In all forms of aluminum-related bone disease, the proportion of osteoid surface covered by osteoblasts is substantially reduced (6, 18, 40, 55, 58, 81, 82) , suggesting that too few osteoblasts are recruited for each new team. Furthermore, bone matrix is made more slowly than normal (55, 58, 82) and wall thickness is reduced, indicating that refilling of resorption cavities is incomplete (82) . As a result, trabeculae are thinner and the amount of cancellous bone reduced (82) .
All of the different morphologic patterns of bone disease mentioned earlier can be accounted for by differences in the relative severity of three separate functional abnormalities: hyperparathyroid bone disease prior to aluminum accumulation, and the alumi- num-related defects in matrix synthesis and in mineralization (Tab. 1). Increased parathyroid hormone secretion increases the rates of remodeling activation, bone formation rate and bone turnover (18, 51) ; resorption cavities are increased in number but also are deeper and more scalloped in shape, giving rise to a more irregularly contoured cement line or bone interface (62, 63, 71) . There is also a qualitative abnormality in osteoblast function with production of woven rather than lamellar bone (18) . Such changes are universal in untreated chronic renal failure (18, 63) , but depending on the completeness of therapeutic control of PTH secretion and on the extent of aluminum-induced inhibition of PTH secretion (83) , the severity will differ markedly between patients, so providing a variety of different settings in which the effects of aluminum can be expressed (84) .
Osteoid thickness reflects the balance between the rate of matrix apposition and the time between matrix synthesis and mineralization, or mineralization lag time (43, 50) . Consequently, the two types of aluminum-related disorders of bone cell function have opposite effects on osteoid thickness, which will be increased by the mineralization defect and decreased by the matrix defect. Only when the former defect is dominant will the classic features of osteomalacia be found, but whether this is generalized or focal (Tab. 1) will depend on the extent to which osteoid surface had been increased by an increase in the birth rate and/or life span of remodeling units (43, 50) . When the matrix defect is dominant, some form of aplastic bone disease will result (40) , but the extent of osteoid accumulation and so the classification as atypical osteomalacia or impaired osteoblast function without osteomalacia will likewise depend on the extent of osteoid surface (Tab. 1). Although the two defects are functionally distinct, the osteoblast is partly responsible for the control of mineralization as well as the synthesis of bone matrix (43) so that an effect of aluminum on osteoblasts could influence the severity of both defects.
Returning now to the other factors that modify the effects of aluminum at the cement line/bone interface, it is likely that one such factor is the intensity of aluminum uptake by osteoblasts and particularly its concentration within mitochondria (44) . Easier removal of aluminum from cells on the bone surface than from the cement line/bone interface could also ac-86 count for the responses to treatment mentioned earlier (67) (68) (69) (70) (71) . Other likely factors include any agent that can alter osteoblast activity, such as parathyroid hormone secretion (82) , the extent of calcitriol production either systemically or locally in bone (51) , and the many other recently described systemic or local growth factors that influence either the proliferation or function of osteoblasts (85) , of which the levels could be influenced by renal failure or by its treatment. Finally, the ability of aluminum to function as a crystal poison may be dependent on its exact physico-chemical state.
Aluminum citrate is a much more potent inhibitor of crystal growth than other aluminum salts (73) , so that anything that changes the concentration of citrate in the extracellular fluid or at the bone interface might determine whether or not mineralization could occur.
Aluminum deposition reduces the rate of bone formation by impairing the recruitment and possibly the activity of osteoblasts (75, 79, 82) , but it has also been suggested that a fall in bone formation rate promotes the uptake of aluminum, with the potential for a vicious circle (2, 7) . Such has been inferred after parathyroidectomy (33, 83, 86, 87) , after corticosteroid therapy to protect a transplanted kidney (3), and in diabetic nephropathy (88) . In each case, a low bone turnover for some reason independent of aluminum is associated with increased aluminum deposition in bone, but this is unlikely to be a simple causal relationship. A reduction in the rate of remodeling activation will reduce the extent of surface corresponding to every stage of the remodeling cycle, including the reversal phase; if reduced activation was the only abnormality, there would be fewer occasions for aluminum deposition, accounting for the protective effect of parathyroidectomy both in the uremic rat (89) and in the non-uremic dog (90) . But a delay in the onset of bone formation, as is frequently found in association with a low rate of bone turnover, would increase the duration of the reversal period and so increase the opportunity for aluminum deposition, as explained earlier. Although there is no necessary connection between the control of cell recruitment and the control of differentiated cell function, these two aspects of bone remodeling frequently change in the same direction (91) .
A few final comments are in order concerning aluminum on the quiescent bone surface. First, because its significance is different from aluminum at the bone interface, the extent of aluminum should be measured and expressed separately in relation to total surface, osteoid surface (or bone interface) and quiescent surface (19) . It is likely that the first will correlate best with total bone aluminum and the second with the disorders of function discussed earlier, although as the osteoid surface increases in extent, the difference between the two methods of expression will diminish. Quiescent surface aluminum has no known harmful effect, but might be related to the disordered calcium homeostasis that is common in patients with aluminum-related bone disease (7) . Since the quiescent surface is normally a site of calcium exchange between blood and bone and participates in the regulation of plasma calcium (92) , the presence of aluminum on the quiescent surface as well as at the bone interface might impair the uptake of calcium by bone and contribute to the excessive rise in plasma calcium that occurs during each dialysis, and may eventually progress to sustained predialysis hypercalcemia and injudicious parathyroid surgery (93) .
Of greater potential importance is the recent observation that in the right circumstances aluminum administration may promote the direct transformation of quiescent surfaces to forming surfaces (94) . The phenomenon bears some resemblance to the therapeutic effect of sodium fluoride, but the arborization of new woven bone into the marrow cavity appears unique to aluminum. Whether aluminum stimulates lining cells to express their latent osteoblast phenotype (14) or promotes the recruitment of new osteoblasts is not clear. It also remains to be determined if this remarkable effect can be exploited in the treatment of osteoporosis. Nevertheless, it provides a further example of the difference between aluminum uptake at the cement line/bone interface and at the quiescent bone surface, the former with the potential for impairment and the latter for enhancement of osteoblast activity.
